Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis

Graves’ orbitopathy (GO) is the most common cause of orbital tissue inflammation, accounting for ~ 60% of all orbital inflammatory conditions in the population aged 21–60 years, and for ~ 40% in the population aged > 60 year. GO is observed in 25–30% of patients with Graves’ hyperthyroidism and more rarely in association with hypothyroid autoimmune thyroiditis. In addition, a small proportion of GO patients (1–2%) do not have a clinically overt thyroid dysfunction. Clinically, GO is characterized by proptosis, inflammation involving the eyelids and the conjunctiva, extraocular muscle hypertrophy, with consequent reduction of ocular motility and diplopia, and in the most severe cases, compression of the optic nerves at the orbital apex, with reduction of visual acuity. At CT scan or MRI, a muscle increase involving the superior, medial and inferior rectus is quite typical. In the most severe forms, compression of the optic nerves at the orbital apex can be observed. Euthyroid GO is usually an early sign of a full-blown Graves’ disease; however, in some cases, the orbital disease can remain isolated. Moreover, euthyroid GO can rarely be unilateral, which makes the picture even more confusing. Under those circumstances, the diagnostic process becomes obviously quite difficult, having other conditions mimicking GO been excluded. A number of inflammatory conditions affecting orbital tissue can mimic GO, thereby requiring an accurate evaluation for a proper differential diagnosis. The majority of these conditions are immune mediated. Most of them are benign, but they can be rather aggressive and some can cause visual loss. The most common inflammatory condition affecting orbital tissues and mimicking GO is idiopathic orbital inflammation. Other, more rare, orbital diseases that should be considered in the differential diagnosis are infections, orbital manifestations of systemic diseases, primitive and secondary orbital neoplasms, and orbital vascular alterations. In most instances, when an orbitopathy occurs in the absence of hyperthyroidism, the diagnosis of the disease underlying the ocular symptoms and signs is based on exclusion of the other conditions. Here we review the conditions that can mimic GO and how to distinguish them from this obnoxious eye disease.

[1]  W. Wiersinga,et al.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy , 1997, Clinical endocrinology.

[2]  L. Bartalena,et al.  Prevalence and natural history of Graves’ orbitopathy in the XXI century , 2013, Journal of Endocrinological Investigation.

[3]  T. Sullivan Vascular Anomalies of the Orbit--A Reappraisal. , 2018, Asia-Pacific journal of ophthalmology.

[4]  W. Wiersinga,et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.

[5]  C. Marcocci,et al.  Mechanistic Pathways of Selenium in the Treatment of Graves’ Disease and Graves’ Orbitopathy , 2018, Hormone and Metabolic Research.

[6]  L. Hegedüs,et al.  Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement , 2017, Orphanet Journal of Rare Diseases.

[7]  L. Chiovato,et al.  Graves’-like orbitopathy: do not forget IgG4-related disease , 2014, Journal of Endocrinological Investigation.

[8]  G. Rose,et al.  Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach , 2017, JAMA ophthalmology.

[9]  P. Dolman Evaluating Graves' orbitopathy. , 2012, Best practice & research. Clinical endocrinology & metabolism.

[10]  M. Stan,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. , 2017, European journal of endocrinology.

[11]  L. Bartalena,et al.  Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? , 2017, Journal of Endocrinological Investigation.

[12]  S. Heegaard,et al.  Orbital lymphoma. , 2019, Survey of ophthalmology.

[13]  C. Marcocci,et al.  Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial , 2018, Journal of Endocrinological Investigation.

[14]  Terry J. Smith,et al.  Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.

[15]  M. Nardi,et al.  Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy. , 2017, Thyroid : official journal of the American Thyroid Association.

[16]  J. Goyal,et al.  Limited Wegener's granulomatosis of the orbit: a case study and review of literature , 2005, Eye.

[17]  M. Nardi,et al.  Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? , 2017, Journal of Endocrinological Investigation.

[18]  W. Wiersinga,et al.  Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. , 2018, The lancet. Diabetes & endocrinology.

[19]  P. Rubin,et al.  Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. , 2003, Archives of ophthalmology.

[20]  M. Nardi,et al.  Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy , 2018, JAMA ophthalmology.

[21]  Terry J. Smith,et al.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. , 2018, Endocrine reviews.

[22]  A. Weber,et al.  Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. , 1999, Radiologic clinics of North America.

[23]  L. Newman,et al.  Medical progress : Sarcoidosis , 1997 .

[24]  A. Sepahdari,et al.  Orbital inflammatory disease: Pictorial review and differential diagnosis. , 2014, World journal of radiology.

[25]  M. Nardi,et al.  Selenium and the course of mild Graves' orbitopathy. , 2011, The New England journal of medicine.

[26]  A. Suri,et al.  Sphenoid wing inflammatory pseudotumor mimicking a clinoidal meningioma: case report and review of the literature. , 2008, Surgical neurology.

[27]  Vikram Deshpande,et al.  IgG4-Related Disease , 2013, International journal of rheumatology.

[28]  C. Marcocci,et al.  A Case of Unilateral Dermopathy Possibly Related to Graves’ Disease , 2019, European Thyroid Journal.

[29]  T. McCulley,et al.  Orbital Disease in Neuro-Ophthalmology. , 2010, Neurologic clinics.

[30]  M. Marinov,et al.  [Orbital lymphoma]. , 2009, Khirurgiia.

[31]  陶仲为 Sarcoidosis , 2009 .

[32]  C. Marcocci,et al.  Studies on the occurrence of ophthalmopathy in Graves' disease. , 1989, Acta endocrinologica.

[33]  M. Nardi,et al.  Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center. , 2015, Thyroid : official journal of the American Thyroid Association.

[34]  M. Nardi,et al.  Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO) , 2018, Journal of Endocrinological Investigation.

[35]  L. Chiovato,et al.  Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy , 2018, Journal of Endocrinological Investigation.

[36]  S. Hickman Optic Perineuritis , 2016, Current Neurology and Neuroscience Reports.

[37]  A. Weber,et al.  Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. , 1999, Radiologic clinics of North America.

[38]  J. V. Pérez-Moreiras,et al.  Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy , 2014, Ophthalmic plastic and reconstructive surgery.

[39]  M. Nardi,et al.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? , 2018, Journal of Endocrinological Investigation.

[40]  R. Nugent,et al.  Optic nerve sheath meningiomas. , 2003, Ophthalmology.

[41]  M. Nardi,et al.  Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy , 2015, Journal of Endocrinological Investigation.

[42]  Yağmur Seda Yeşiltaş,et al.  Idiopathic Orbital Inflammation: Review of Literature and New Advances , 2018, Middle East African journal of ophthalmology.

[43]  J. Stone,et al.  IgG4-related disease. , 2012, The New England journal of medicine.

[44]  L. Chiovato,et al.  Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited , 2004, Journal of endocrinological investigation.

[45]  B. Schoser,et al.  “Orbiting around” the orbital myositis: clinical features, differential diagnosis and therapy , 2015, Journal of Neurology.

[46]  Z. Ding,et al.  Idiopathic orbital pseudotumour. , 2011, Clinical radiology.

[47]  M. Rotondi,et al.  DIAGNOSIS OF ENDOCRINE DISEASE: IgG4-related thyroid autoimmune disease. , 2019, European journal of endocrinology.

[48]  R. Bahn Current Insights into the Pathogenesis of Graves’ Ophthalmopathy , 2015, Hormone and Metabolic Research.

[49]  C. Shields,et al.  Overview of benign and malignant lacrimal gland tumors , 2018, Current opinion in ophthalmology.

[50]  E. Bonfá,et al.  Sjögren’s syndrome and systemic lupus erythematosus: links and risks , 2019, Open access rheumatology : research and reviews.

[51]  J. Rosenbaum,et al.  Orbital inflammatory disease. , 2008, Seminars in arthritis and rheumatism.

[52]  Christine O Menias,et al.  Inflammatory pseudotumor: the great mimicker. , 2012, AJR. American journal of roentgenology.

[53]  C. Marcocci,et al.  Management of Graves' ophthalmopathy: reality and perspectives. , 2000, Endocrine reviews.

[54]  L. Sánchez,et al.  [Idiopathic orbital myositis]. , 1999, Medicina clinica.

[55]  C. Marcocci,et al.  Selenium in Graves Hyperthyroidism and Orbitopathy. , 2018, Ophthalmic plastic and reconstructive surgery.

[56]  Jianhua Yan,et al.  Idiopathic Orbital Myositis , 2014, The Journal of craniofacial surgery.